OTCPK:PRLX

Stock Analysis Report

Parallax Health Sciences

Executive Summary

Parallax Health Sciences, Inc. builds and expands an integrated digital healthcare network with products and services that can provide remote communication, diagnosis, treatment, and monitoring of patients on a proprietary platform.

Snowflake

Fundamentals

Slightly overvalued with questionable track record.

Risks

  • Parallax Health Sciences has significant price volatility in the past 3 months.
  • Parallax Health Sciences is not covered by any analysts.

Similar Companies

Share Price & News

How has Parallax Health Sciences's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

28.1%

PRLX

1.6%

US Healthcare Services

-0.6%

US Market


1 Year Return

-31.7%

PRLX

9.9%

US Healthcare Services

0.7%

US Market

PRLX underperformed the Healthcare Services industry which returned 10.2% over the past year.

PRLX underperformed the Market in United States of America which returned 0.7% over the past year.


Share holder returns

PRLXIndustryMarket
7 Day28.1%1.6%-0.6%
30 Day0.5%-0.06%4.9%
90 Day-14.6%-1.4%1.7%
1 Year-31.7%-31.7%10.0%9.9%3.0%0.7%
3 Year60.2%60.2%52.6%52.2%44.8%35.4%
5 Year-16.0%-16.0%51.7%50.8%62.0%44.3%

Price Volatility Vs. Market

How volatile is Parallax Health Sciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Parallax Health Sciences undervalued based on future cash flows and its price relative to the stock market?

0.85x

Price to Earnings (PE) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Parallax Health Sciences to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Parallax Health Sciences to establish if it is available at substantial discount.


Price Based on Earnings

Parallax Health Sciences is good value based on earnings compared to the US Healthcare Services industry average.

Parallax Health Sciences is good value based on earnings compared to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Parallax Health Sciences, we can't assess if its growth is good value.


Price Based on Value of Assets

Parallax Health Sciences has negative assets, we can't compare the value of its assets to the US Healthcare Services industry average.


Next Steps

Future Growth

How is Parallax Health Sciences expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

27.7%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Parallax Health Sciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of PRLX’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Parallax Health Sciences's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has Parallax Health Sciences performed over the past 5 years?

25.3%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Parallax Health Sciences has delivered over 20% year on year earnings growth in the past 5 years.

Parallax Health Sciences has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.

Parallax Health Sciences has become profitable in the last year making it difficult to compare the US Healthcare Services industry average.


Return on Equity

It is difficult to establish if Parallax Health Sciences has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.


Return on Assets

Parallax Health Sciences used its assets more efficiently than the US Healthcare Services industry average last year based on Return on Assets.


Return on Capital Employed

It is difficult to establish if Parallax Health Sciences improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.


Next Steps

Financial Health

How is Parallax Health Sciences's financial position?


Financial Position Analysis

Parallax Health Sciences's short term (1 year) commitments are greater than its holdings of cash and other short term assets.

Parallax Health Sciences's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

Parallax Health Sciences has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.

Irrelevant to check if Parallax Health Sciences's debt level has increased considering it has negative shareholder equity.

Operating cash flow is negative therefore debt is not well covered.

Unable to confirm if the interest payments on Parallax Health Sciences's debt are well covered by earnings due to lack of past financial data.


Balance Sheet

Low level of unsold assets.

Parallax Health Sciences has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Next Steps

Dividend

What is Parallax Health Sciences's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Parallax Health Sciences's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Parallax Health Sciences's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Parallax Health Sciences has not reported any payouts.

Unable to verify if Parallax Health Sciences's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Parallax Health Sciences has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Parallax Health Sciences's salary, the management and board of directors tenure and is there insider trading?

2.9yrs

Average management tenure


CEO

Paul Arena (60yo)

2.2yrs

Tenure

0

Mr. Paul R. Arena has been the Chairman, Chief Executive Officer and President of AIM Group, Inc. since May 2000. He serves as the Chief Executive Officer President and Director of Parallax Health Sciences ...


Management Age and Tenure

2.9yrs

Average Tenure

55yo

Average Age

The tenure for the Parallax Health Sciences management team is about average.


Board Age and Tenure

2.4yrs

Average Tenure

60yo

Average Age

The average tenure for the Parallax Health Sciences board of directors is less than 3 years, this suggests a new board.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Paul Arena (60yo)

    CEO, President & Director

    • Tenure: 2.2yrs
  • David Appell (56yo)

    Chief Operating Officer

    • Tenure: 0.3yrs
  • Nathan Bradley (42yo)

    CTO & Director

    • Tenure: 1.3yrs
  • Calli Bucci (54yo)

    CFO, Principal Accounting Officer

    • Tenure: 2.7yrs
    • Compensation: US$157.45k
  • David Stark

    Chief Regulatory Officer

    • Tenure: 0yrs

Board Members

  • Paul Arena (60yo)

    CEO, President & Director

    • Tenure: 2.2yrs
  • Nathan Bradley (42yo)

    CTO & Director

    • Tenure: 1.3yrs
  • John Ogden (65yo)

    Director

    • Tenure: 0yrs
  • Bill Withrow (79yo)

    Director

    • Tenure: 6.8yrs
  • Calli Bucci (54yo)

    CFO, Principal Accounting Officer

    • Tenure: 2.7yrs
    • Compensation: US$157.45k

Company Information

Parallax Health Sciences, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Parallax Health Sciences, Inc.
  • Ticker: PRLX
  • Exchange: OTCPK
  • Founded: 2005
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: US$19.682m
  • Shares outstanding: 192.01m
  • Website: https://www.parallaxhealthsciences.com

Number of Employees


Location

  • Parallax Health Sciences, Inc.
  • 1327 Ocean Avenue
  • Suite B
  • Santa Monica
  • California
  • 90401
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PRLXOTCPK (Pink Sheets LLC)YesNew Common StockUSUSDOct 2012

Biography

Parallax Health Sciences, Inc. builds and expands an integrated digital healthcare network with products and services that can provide remote communication, diagnosis, treatment, and monitoring of patients ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/23 00:23
End of Day Share Price2019/09/19 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.